Education
About Us
Working with TipRanks
Follow Us
Amgen (AMGN)
NASDAQ:AMGN
Earnings Data
Report Date
Aug 05, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
5.23Last Year’s EPS
4.97Same Quarter Last Year
Moderate Buy
Based on 21 Analysts Ratings
Earnings Call Summary
Earnings Call Date:May 01, 2025
|% Change Since: -3.54%
|Next Earnings Date:Aug 05, 2025
Earnings Call Sentiment|Positive
The earnings call reflects a strong performance with notable revenue and volume growth, successful biosimilar launches, and strategic expansions. However, there are concerns regarding potential impacts from tariffs and tax uncertainties, as well as challenges in maintaining inventory levels in the rare disease segment.Company Guidance
During the Amgen Q1 FY 2025 earnings call, the company reported a robust start to the year with a 9% year-over-year revenue increase and 14% volume growth, driven by strong patient demand. Amgen highlighted double-digit sales growth across 14 medicines, spanning general medicine, rare diseases, inflammation, and oncology. Their biosimilars portfolio contributed over $700 million in revenue, a 35% increase compared to the previous year. Significant milestones included multiple positive Phase III data readouts, initiation of four new Phase III studies, and three new product or indication launches. Key growth drivers mentioned were Repatha, which saw a 27% increase in sales, and EVENITY, which grew 29%, while their rare disease portfolio, including UPLIZNA and TEPEZZA, positioned for long-term growth. The company also emphasized ongoing investments in their late-stage pipeline and manufacturing expansions, maintaining a forward-looking outlook despite uncertainties in tariffs and taxes. Overall, Amgen expressed confidence in continuing their trajectory of innovation and growth.Strong Revenue Growth
Revenue grew 9% year-over-year with a significant volume growth of 14% reflecting increased patient demand.
Biosimilars Portfolio Success
The biosimilars portfolio delivered more than $700 million in revenue this quarter, up 35% year-over-year.
Positive Phase III Data and New Product Launches
Delivered multiple positive Phase III readouts, initiated four new Phase III studies, and launched three new products or indications.
Growth in Rare Disease Portfolio
UPLIZNA, a differentiated B-cell depleting therapy, showed promise with recent FDA approval for IgG4-related disease and strong early-stage reception.
Oncology Developments
BLINCYTO and IMDELLTRA continued to grow, with IMDELLTRA showing significant survival benefits in second-line small cell lung cancer.
Expansion of Manufacturing
Amgen announced nearly $2 billion in additional expansions in Ohio and North Carolina.
Improved Access for Repatha
Repatha sales increased 27% year-over-year, driven by improved access and patient activation efforts.
AMGN Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
AMGN Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 01, 2025 | $281.29 | $278.76 | -0.90% |
Feb 04, 2025 | $284.19 | $302.67 | +6.50% |
Oct 30, 2024 | $307.81 | $312.31 | +1.46% |
Aug 06, 2024 | $318.67 | $302.73 | -5.00% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Amgen (AMGN) report earnings?
Amgen (AMGN) is schdueled to report earning on Aug 05, 2025, TBA Not Confirmed.
What is Amgen (AMGN) earnings time?
Amgen (AMGN) earnings time is at Aug 05, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is AMGN EPS forecast?
AMGN EPS forecast for the fiscal quarter 2025 (Q2) is 5.23.
